MedPath

Observational Study Evaluating Rituximab Use and Use of the Patient Alert Card in Participants Receiving Rituximab Infusion for a Non-Oncology Indication at Infusion Centers in Europe

Completed
Conditions
Off-Label Use
Registration Number
NCT02654379
Lead Sponsor
Hoffmann-La Roche
Brief Summary

This study is to characterize the indications for which rituximab is being used and to evaluate the use of the Patient Alert Card (PAC) in participants receiving the medication for non-oncology conditions at infusion centers. The study involves the retrospective chart review of rituximab users' medical records in non-oncology indications as well as a survey to collect information on participant characteristics, and will include questions about participant knowledge on the risk of infections, participant receipt and review of the PAC, and any actions the participant has taken as a result of receiving the PAC.

Detailed Description

Not available

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1408
Inclusion Criteria
  • Participant is in the center to receive an infusion for rituximab for a non-oncology indication during the study period
  • Aged 18 years or older
Exclusion Criteria
  • Has previously already completed the rituximab survey
  • Has participated in the past 12 months in a clinical trial in which rituximab was one of the treatments being evaluated.

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Aware of Known and Potential Risks of Infection Associated with RituximabUp to 10 months
Percentage of Participants Using Rituximab Off-LabelUp to 10 months
Secondary Outcome Measures
NameTimeMethod
Percentage of Participants Who Received the Patient Alert Card (PAC)Up to 10 months
Percentage of Participants Who Received Additional Safety-Related MaterialsUp to 10 months
Disease Activity Score Based on 28 Joints (DAS28) for Participants with Rheumatoid Arthritis (RA)Up to 10 months
Percentage of Participants Who Read the PACUp to 10 months

Trial Locations

Locations (48)

Chu De Clermont Ferrand; Hopital Gabriel Montpied

🇫🇷

Clermont Ferrand, France

Centre Hospitalier Sud Francilien

🇫🇷

Corbeil Essonnes, France

Centre Hospitalier Le Mans

🇫🇷

Le Mans, France

Hopital Claude Huriez - CHU Lille

🇫🇷

Lille, France

Hôpital Lapeyronie

🇫🇷

Montpellier, France

CHU NANTES - Hôtel Dieu; Pharmacy

🇫🇷

Nantes, France

Hôpital Cochin

🇫🇷

Paris, France

Groupe Hospitalier Sud - Hôpital Haut-Lévêque - Centre François Magendie

🇫🇷

Pessac, France

CHU Saint-Etienne, Hopital Bellevue

🇫🇷

Saint-Etienne, France

CHU de Toulouse - Hôpital Purpan

🇫🇷

Toulouse, France

Scroll for more (38 remaining)
Chu De Clermont Ferrand; Hopital Gabriel Montpied
🇫🇷Clermont Ferrand, France

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.